Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer    BAYN   DE000BAY0017

BAYER (BAYN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Bayer Stops Sale of Glucose Meter Business

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/09/2013 | 12:07pm CEST

By Hendrik Varnholt

FRANKFURT--German pharmaceutical company Bayer AG (>> Bayer AG) will retain its blood glucose meter business, a spokeswoman said Wednesday, confirming a Bloomberg report.

Bayer had put up the unit for sale and had been in talks with French peer Sanofi SA (>> SANOFI) about a deal which could have been valued at around $1.5 billion, people familiar with the matter told Dow Jones Newswires in December.

"We have evaluated several options and decided to retain it," Bayer HealthCare chief Joerg Reinhardt said about the glucose meter business, according to Bloomberg.

Natali Schwab, Eyk Henning and Dana Cimilluca contributed to this story.

Write to Hendrik Varnholt at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bayer AG, SANOFI
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER
10/19 BAYER : Recent Findings from Bayer Has Provided New Data on Melanoma (Super-enha..
10/19 FINDINGS FROM BAYER PROVIDE NEW INSI : a nested...
10/19 BAYER : submits its extended half - life hemophilia a compound for marketing aut..
10/18 BAYER : to fund three youth-led food security projects
10/17 BAYER : foundations bring tech pioneers physicians and social entrepreneurs to t..
10/16 BAYER : Health and Human Services Department (HHS); Food and Drug Administration..
10/14DJBAYER : Unloads Assets to Aid Deal -- WSJ
10/13 BASF CEO says to look at more seed M&A after Bayer deal
10/13 Bayer sells units to be able to complete Monsanto takeover
10/13 BAYER : foundations bring tech pioneers, physicians and social entrepreneurs to ..
More news
News from SeekingAlpha
04:16a Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/17 Monsanto Ending On A Position Of Strength
10/16 BASF (BASFY) To Acquire Significant Parts Of Bayer's (BAYZF) Seed And Non-Sel..
10/14 BASF Buys Bayer's Crop Science Assets At A Fair Price
10/13 WALL STREET BREAKFAST : The Beat Goes On For Global Stocks As Records Continue T..
Financials (€)
Sales 2017 47 846 M
EBIT 2017 9 231 M
Net income 2017 5 397 M
Debt 2017 12 235 M
Yield 2017 2,34%
P/E ratio 2017 19,53
P/E ratio 2018 17,71
EV / Sales 2017 2,31x
EV / Sales 2018 2,20x
Capitalization 98 159 M
Chart BAYER
Duration : Period :
Bayer Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Technical analysis trends BAYER
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 121 €
Spread / Average Target 1,9%
EPS Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Head-Human Resources, Technology & Sustainability
Sector and Competitors
1st jan.Capitalization (M$)
BAYER19.94%115 989
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372
MERCK AND COMPANY7.88%173 214